The recurrence-free survival was 33% within the Opdivo group and surgery-only group in sure sufferers with kidney most cancers. Including Opdivo (nivolumab) earlier...
Responses to Iclusig doubled that of Gleevec in sufferers with Philadelphia chromosome-positive acute lymphoblastic leukemia, analysis confirmed.Sufferers with newly recognized Philadelphia chromosome-positive acute...